TY - JOUR
T1 - Primary CNS lymphoma in children and adolescents
T2 - A descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)
AU - Abla, Oussama
AU - Weitzman, Sheila
AU - Blay, Jean Yves
AU - O'Neill, Brian Patrick
AU - Abrey, Lauren E.
AU - Neuwelt, Edward
AU - Doolittle, Nancy D.
AU - Baehring, Joachim
AU - Pradhan, Kamnesh
AU - Martin, S. Eric
AU - Guerrera, Michael
AU - Shah, Shafqat
AU - Ghesquieres, Hervé
AU - Silver, Michael
AU - Betensky, Rebecca A.
AU - Batchelor, Tracy
PY - 2011/1/15
Y1 - 2011/1/15
N2 - Purpose: To describe the demographic and clinical features and outcomes for children and adolescents with primary CNS lymphoma (PCNSL). Experimental Design: A retrospective series of children and adolescents with PCNSL was assembled from 10 cancer centers in 3 countries. Results: Twenty-nine patients with a median age of 14 years were identified. Sixteen (55%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1 or greater. Frontline therapy consisted of chemotherapy only in 20 patients (69%), while 9 (31%) had chemotherapy plus cranial radiotherapy. Most patients received methotrexate (MTX)-based regimens. Overall response rate was 86% (complete remission 69%, partial remission 17%). The 2-year progression-free survival (PFS) and overall survival (OS) rates were 61% and 86%, respectively; the 3-year OS was 82%. Univariate analyses were conducted for age (≤14 vs. >14 years), PS (0 or 1 vs. >1), deep brain lesions, MTX dose, primary treatment with chemotherapy alone, intrathecal chemotherapy, and high-dose therapy. Primary treatment with chemotherapy alone was associated with better overall response rates with an odds ratio (OR) of 0.125 (P = 0.02). There was a marginally significant relationship between higher doses of MTX and response (OR = 1.5, P = 0.06). ECOG-PS of 0 to 1 was the only factor associated with better outcome with hazard ratios of 0.136 (P = 0.017) and 0.073 (P = 0.033) for PFS and OS, respectively. Conclusion: This is the largest series collected of pediatric PCNSL. The outcome of children and adolescents seems to be better than in adults. PS of 0 to 1 is associated with better survival.
AB - Purpose: To describe the demographic and clinical features and outcomes for children and adolescents with primary CNS lymphoma (PCNSL). Experimental Design: A retrospective series of children and adolescents with PCNSL was assembled from 10 cancer centers in 3 countries. Results: Twenty-nine patients with a median age of 14 years were identified. Sixteen (55%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1 or greater. Frontline therapy consisted of chemotherapy only in 20 patients (69%), while 9 (31%) had chemotherapy plus cranial radiotherapy. Most patients received methotrexate (MTX)-based regimens. Overall response rate was 86% (complete remission 69%, partial remission 17%). The 2-year progression-free survival (PFS) and overall survival (OS) rates were 61% and 86%, respectively; the 3-year OS was 82%. Univariate analyses were conducted for age (≤14 vs. >14 years), PS (0 or 1 vs. >1), deep brain lesions, MTX dose, primary treatment with chemotherapy alone, intrathecal chemotherapy, and high-dose therapy. Primary treatment with chemotherapy alone was associated with better overall response rates with an odds ratio (OR) of 0.125 (P = 0.02). There was a marginally significant relationship between higher doses of MTX and response (OR = 1.5, P = 0.06). ECOG-PS of 0 to 1 was the only factor associated with better outcome with hazard ratios of 0.136 (P = 0.017) and 0.073 (P = 0.033) for PFS and OS, respectively. Conclusion: This is the largest series collected of pediatric PCNSL. The outcome of children and adolescents seems to be better than in adults. PS of 0 to 1 is associated with better survival.
UR - http://www.scopus.com/inward/record.url?scp=79251491741&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79251491741&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-10-1161
DO - 10.1158/1078-0432.CCR-10-1161
M3 - Article
C2 - 21224370
AN - SCOPUS:79251491741
SN - 1078-0432
VL - 17
SP - 346
EP - 352
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 2
ER -